Visit coverage vs medication coverage
The visit and the medication are often covered under different parts of the plan. Patients can have one covered and the other denied.
The main cost question has three separate layers: the visit, the medication, and the follow-up cadence. Insurance may cover the visit while denying the medication, or cover the medication only after prior authorization. Self-pay visits are available when patients want to move forward without waiting on benefit review. Commercial savings programs may help some patients, but those rules change, so the current pharmacy path matters more than a generic online number.
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking.
Tirzepatide is the ingredient in Mounjaro and Zepbound. Mounjaro is approved with diet and exercise to improve glucose control in adults and children age 10 and older with type 2 diabetes. Under its August 2026 US label, it also reduces the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk. These events are cardiovascular death, nonfatal heart attack or nonfatal stroke. That cardiovascular indication is for adults. Zepbound has separate approvals for adult weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. These approvals do not extend to compounded tirzepatide.
Zepbound weight treatment is for adults with obesity or overweight and a weight-related condition. The OSA indication needs the specified diagnosis and obesity. Mounjaro’s pediatric diabetes approval does not create a pediatric Zepbound weight indication.
Review the diagnosis, medicine history and risks. Both approved tirzepatide brands start at 2.5 mg once weekly, but follow their separate schedules. The August 2026 Mounjaro label permits 2.5 mg increases after at least four weeks on the current dose if additional glucose control is needed. Its maximum is 15 mg weekly for adults and 10 mg for pediatric patients. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg. Its maintenance dose depends on weight or OSA treatment and tolerability. Increase only under the prescriber’s plan. Train for the exact vial or pen received and arrange monitoring and refills.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Use a non-oral contraceptive method or add a barrier method for four weeks after starting tirzepatide and after each dose increase. Do not overlap tirzepatide products or another GLP-1 medicine without a clinician’s plan.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Ask for separate current estimates for the evaluation, required tests, medicine, administration when relevant, and follow-up. Drug costs depend on product, dose, coverage, pharmacy, and savings eligibility. Self-pay still requires clinical review and monitoring. Confirm any manufacturer program’s current terms directly; a posted price does not guarantee your final cost.
Yes, an insurance plan can cover a consultation while excluding the medicine or denying its authorization. They are separate benefit decisions. Confirm the selected clinic’s visit participation and the exact tirzepatide product, indication, pharmacy charge and authorization outcome. A paid appointment does not establish coverage or affordable continuation of the drug.
Ask the selected Nao clinic about current self-pay weight-management consultation charges and what the visit includes. Medicine, testing and follow-up may add separate costs. A self-pay visit still requires clinical assessment and does not guarantee a tirzepatide prescription; confirm the full care and refill budget before starting.
As of October 9, 2026, LillyDirect advertises a self-pay purchase price starting at $499 per month for Mounjaro single-dose pens across its six strengths. Its program requires an FDA-approved use, US or Puerto Rico residence and age 18 or older, and defines a month as four pens. Purchases cannot be submitted for insurance reimbursement or counted toward deductible or out-of-pocket requirements. This adult purchase program is separate from Mounjaro’s pediatric diabetes approval. Confirm current terms, taxes, fees and your pharmacy’s price. Medical visits and tests are separate.
The visit and the medication are often covered under different parts of the plan. Patients can have one covered and the other denied.
Coverage commonly depends on documented BMI, comorbidities, previous attempts, formulary rules, and whether weight-loss drugs are excluded by the employer plan.
Some commercially insured patients may have access to manufacturer savings programs, but those rules change and should be treated as a moving target rather than a guaranteed price.
The cheapest start is not always the best long-term fit if the monitoring path, dose availability, or refill plan is unstable.
Bronx
932 E 174th St, Bronx, NY 10460
A Bronx access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods.
View local weight-loss details Get directions
Queens
37-15 23rd Ave, Astoria, NY 11105
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods.
View local weight-loss details Get directions
Bronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods.
View local weight-loss details Get directions
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A Brooklyn access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods.
View local weight-loss details Get directions
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A Long Island access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Hicksville, Plainview, Bethpage, and nearby Nassau County communities.
View local weight-loss details Get directions
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods.
View local weight-loss details Get directions
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods.
View local weight-loss details Get directions
Queens
30-07 36th Ave, Astoria, NY 11106
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods.
View local weight-loss details Get directions
Long Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Mineola, Garden City, Westbury, and nearby Nassau County communities.
View local weight-loss details Get directions
Manhattan
259 1st Ave, New York, NY 10003
A Manhattan access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods.
View local weight-loss details Get directions
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A Brooklyn access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods.
View local weight-loss details Get directions
Confirm the visit, testing and treatment costs separately with the clinic and your insurer.
Open main tirzepatide overview